Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Inclisiran bulk supplier for pharma manufacturers

Inclisiran 300 mg Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 300 mg

Reference Brands: Leqvio (USA/EU)

Category: Heart Disorder

Inclisiran is a small interfering RNA (siRNA) therapy that works by reducing the production of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in the liver, which in turn increases the number of LDL receptors and helps remove more LDL cholesterol from the blood. It is used to lower LDL cholesterol in patients with high cholesterol (hypercholesterolemia) or atherosclerotic cardiovascular disease, especially when statins alone are insufficient or not tolerated.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Inclisiran — third party manufacturing & bulk supply

Inclisiran 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Inclisiran listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Inclisiran →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Inclisiran is used to lower low‑density lipoprotein cholesterol (LDL‑C) in adults with high cholesterol, including those with heterozygous familial hypercholesterolemia, and in people with atherosclerotic cardiovascular disease who need additional LDL‑C reduction beyond diet and maximally tolerated statin therapy.

Inclisiran is a synthetic small interfering RNA (siRNA), a chemically modified double‑stranded oligonucleotide that targets mRNA for the protein PCSK9 in liver cells, preventing its production.

The trade name of Inclisiran is Leqvio.

Inclisiran (Leqvio) is manufactured and marketed by Novartis.

The generic name is Inclisiran.

The brand name is Leqvio.

Inclisiran is produced by Novartis under global regulatory approvals.

Related Products

Trandolapril

Strength:
0.5 mg, 1 mg, 2 mg

Form: Tablets

Reference Brands: Mavik (USA), Gopten (EU)

View Details
Tirofiban Hydrochloride

Strength:
2.5 mg/mL

Form: Injection

Reference Brands: Aggrastat (USA)

View Details
Selexipag

Strength:
200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg

Form: Tablets / Injection

Reference Brands: Uptravi (USA/EU)

View Details
Edoxaban

Strength:
15 mg, 30 mg, 60 mg

Form: Tablets

Reference Brands: Savaysa (USA), Lixiana (EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.